Literature DB >> 17617878

Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer.

E Oki1, M Morita, Y Kakeji, M Ikebe, N Sadanaga, A Egasira, K Nishida, T Koga, M Ohata, T Honboh, M Yamamoto, H Baba, Y Maehara.   

Abstract

Salvage esophagectomy is performed for esophageal cancer after definitive chemoradiotherapy. The clinical significance and safety of salvage surgery has not been well established. We reviewed 14 cases of salvage esophagectomy following definitive chemoradiotherapy from 1994 through 2005 and investigated complication rates and outcomes. Seven of 14 cases were completely resected with salvage surgery. Operation time and bleeding were greater in patients who experienced incomplete resection (R1/R2). Anastomosis leakage, pulmonary dysfunction and heart failure were recognized in four, two and one patients, respectively. The postoperative complications were more frequent (71.4%) in patients with incomplete resection (R1/R2) than in patients with complete resection (R0) (28.4%). Two patients with complete resection (R0) showed long-term survival. Salvage esophagectomy may be indicated when the tumor can be resected completely after definitive chemotherapy. However, all cases of T4 cancer cannot be resected completely, resulting in a high risk for complications and poor survival.

Entities:  

Mesh:

Year:  2007        PMID: 17617878     DOI: 10.1111/j.1442-2050.2007.00677.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  14 in total

1.  Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy.

Authors:  Masaru Morita; Ryuichi Kumashiro; Yuichi Hisamatsu; Ryota Nakanishi; Akinori Egashira; Hiroshi Saeki; Eiji Oki; Takefumi Ohga; Yoshihiro Kakeji; Shunichi Tsujitani; Takeharu Yamanaka; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2011-08-05       Impact factor: 7.527

2.  Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation.

Authors:  Stephen G Swisher; Jenifer Marks; David Rice
Journal:  Ann Cardiothorac Surg       Date:  2017-03

Review 3.  Current management of esophageal cancer.

Authors:  Xavier Benoit D'Journo; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 4.  Salvage esophagectomy: safe therapeutic strategy?

Authors:  Sara Jamel; Sheraz R Markar
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

5.  Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma.

Authors:  Akihiko Okamura; Masaru Hayami; Ryotaro Kozuki; Keita Takahashi; Tasuku Toihata; Yu Imamura; Shinji Mine; Masayuki Watanabe
Journal:  Esophagus       Date:  2019-10-08       Impact factor: 4.230

Review 6.  Role of salvage esophagectomy after definitive chemoradiotherapy.

Authors:  Yuji Tachimori
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-02-12

7.  Definitive chemoradiotherapy and salvage esophagectomy for esophageal cancer associated with multiple lung metastases: a case report.

Authors:  Yoshihiko Fujinaka; Masaru Morita; Takefumi Ohga; Yoshihiro Kakeji; Tokujiro Yano; Yoshihiko Maehara
Journal:  Int Surg       Date:  2014 Sep-Oct

Review 8.  Salvage esophagectomy.

Authors:  Wayne L Hofstetter
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 9.  Surgical strategies for esophageal cancer associated with head and neck cancer.

Authors:  Masaru Morita; Hiroshi Saeki; Shuhei Ito; Yasue Kimura; Nami Yamashita; Koji Ando; Yukiharu Hiyoshi; Eriko Tokunaga; Eiji Oki; Tetsuo Ikeda; Sei Yoshida; Torahiko Nakashima; Yoshihiko Maehara
Journal:  Surg Today       Date:  2013-08-30       Impact factor: 2.549

10.  Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.

Authors:  Kazuki Sudo; Takashi Taketa; Arlene M Correa; Maria-Claudia Campagna; Roopma Wadhwa; Mariela A Blum; Ritsuko Komaki; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Heath D Skinner; Dipen M Maru; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.